Damien Drubay

Damien Drubay

Auto-generated profile, based on publicly available information

Damien Drubay

Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell
Verified
Journal Article
Closed access
ASAymeric Silvin
Aymeric Silvin
Nicolas ChapuisNicolas Chapuis
Nicolas Chapuis
GDGarett Dunsmore
Garett Dunsmore
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
ADAgathe Dubuisson
Agathe Dubuisson
ESEric Solary
Eric Solary

1 March 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SLSherene Loi
Sherene Loi
DDDamien Drubay
Damien Drubay
SASylvia Adams
Sylvia Adams
GPGiancarlo Pruneri
Giancarlo Pruneri
PFPrudence A. Francis
Prudence A. Francis
SMStefan Michiels
Stefan Michiels
Purpose: The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). Methods: Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes. Cox proportional hazards regression models stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. Results: We collected individual data from 2,148 patients from nine studies. Average age was 50 years (range, 22 to 85 years), and 33% of patients were node negative. The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with older age ( P = .001), larger tumor size ( P = .01), more nodal involvement ( P = .02), and lower histologic grade ( P = .001). A total of 736 iDFS and 548 D-DFS events and 533 deaths were observed. In the multivariable model, sTILs added significant independent prognostic information for all end points (likelihood ratio χ2, 48.9 iDFS; P < .001; χ2, 55.8 D-DFS; P < .001; χ2, 48.5 OS; P < .001). Each 10% increment in sTILs corresponded to an iDFS hazard ratio of 0.87 (95% CI, 0.83 to 0.91) for iDFS, 0.83 (95% CI, 0.79 to 0.88) for D-DFS, and 0.84 (95% CI, 0.79 to 0.89) for OS. In node-negative patients with sTILs ≥ 30%, 3-year iDFS was 92% (95% CI, 89% to 98%), D-DFS was 97% (95% CI, 95% to 99%), and OS was 99% (95% CI, 97% to 100%). Conclusion: This pooled data analysis confirms the strong prognostic role of sTILs in early-stage TNBC and excellent survival of patients with high sTILs after adjuvant chemotherapy and supports the integration of sTILs in a clinicopathologic prognostic model for patients with TNBC. This model can be found at www.tilsinbreastcancer.org .

3 February 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LDLisa Derosa
Lisa Derosa
BRBertrand Routy
Bertrand Routy
ATAndrew Thomas
Andrew Thomas
Valerio IebbaValerio Iebba
Valerio Iebba
GZGérard Zalcman
Gérard Zalcman
BBBenjamin Besse
Benjamin Besse

25 January 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
GFGladys Ferrere
Gladys Ferrere
MAMaryam Tidjani Alou
Maryam Tidjani Alou
PLPeng Liu
Peng Liu
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
MFMarine Fidelle
Marine Fidelle
LZLaurence Zitvogel
Laurence Zitvogel
Limited experimental evidence bridges nutrition and cancer immunosurveillance. Here, we show that ketogenic diet (KD) — or its principal ketone body, 3-hydroxybutyrate (3HB), most specifically in intermittent scheduling — induced T cell–dependent tumor growth retardation of aggressive tumor models. In conditions in which anti–PD-1 alone or in combination with anti–CTLA-4 failed to reduce tumor growth in mice receiving a standard diet, KD, or oral supplementation of 3HB reestablished therapeutic responses. Supplementation of KD with sucrose (which breaks ketogenesis, abolishing 3HB production) or with a pharmacological antagonist of the 3HB receptor GPR109A abolished the antitumor effects. Mechanistically, 3HB prevented the immune checkpoint blockade–linked upregulation of PD-L1 on myeloid cells, while favoring the expansion of CXCR3 + T cells. KD induced compositional changes of the gut microbiota, with distinct species such as Eisenbergiella massiliensis commonly emerging in mice and humans subjected to carbohydrate-low diet interventions and highly correlating with serum concentrations of 3HB. Altogether, these results demonstrate that KD induces a 3HB-mediated antineoplastic effect that relies on T cell–mediated cancer immunosurveillance.

19 January 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JTJean Ogier du Terrail
Jean Ogier du Terrail
ALArmand Leopold
Armand Leopold
CJClément Joly
Clément Joly
CBConstance Béguier
Constance Béguier
MAMathieu Andreux
Mathieu Andreux
PHPierre Etienne HEUDEL
Pierre Etienne HEUDEL

20 November 2014 in International Archives of Occupational and Environmental Health
Verified
Journal Article
Closed access
PDF file
EREstelle Rage
Estelle Rage
SCS. Caër-Lorho
S. Caër-Lorho
DDD. Drubay
D. Drubay
SAS. Ancelet
S. Ancelet
PLP. Laroche
P. Laroche
DLD. Laurier
D. Laurier